Accessibility Skip to Global Navigation Skip to Local Navigation Skip to Content Skip to Search Skip to Site Map Menu

Health Sciences profile

Dr David Finlay

PositionPostdoctoral Fellow
DepartmentDepartment of Pharmacology and Toxicology
QualificationsBSc PGDipSci MSc(Hons) PhD
Research summaryCannabinoids, G protein-coupled receptors, cell signalling, molecular pharmacology, receptor theory

Research

My research area of interest is the molecular pharmacology of cannabinoid receptors and their ligands. The focus of my recent PhD research was non-canonical CB1 signalling, and the functional selectivity of CB1 agonists (the ability of different drugs to preferentially activate different signalling pathways). This is underpinned by a broader interest in disease aetiology and drug discovery as they relate to the function of G protein-coupled receptors (of which the cannabinoid receptors are an example). I also have an interest in receptor theory and participate in collaborations in this area.

Current projects involve research into the molecular characteristics of synthetic cannabinoids. These are a rapidly proliferating class of drugs of abuse (including in New Zealand), which are of increasing concern because of their negative social effects and physiological toxicity – for example, AMB-FUBINACA is a synthetic cannabinoid now believed to be involved in the deaths of several dozen New Zealanders. The mechanism(s) by which these compounds exert their toxic effects is currently unknown.

Publications

Gamage, T. F., Barrus, D. A., Kevin, R. C., Finlay, D. B., Lefever, T. W., Patel, P. R., … Glass, M., … Thomas, B. F. (2020). In vitro and in vivo pharmacological evaluation of the synthetic cannabinoid receptor agonist EG-018. Pharmacology Biochemistry & Behavior, 193, 172918. doi: 10.1016/j.pbb.2020.172918

Mielnik, C. A., Sugamori, K. S., Finlay, D. B., Thorpe, H. H. A., Schapira, M., Sivananthan, N., … Glass, M., … Ross, R. A. (2020). A novel allosteric modulator of the cannabinoid CB1 receptor ameliorates hyperdopaminergia endophenotypes in rodent models. Neuropsychopharmacology. Advance online publication. doi: 10.1038/s41386-020-00876-5

Patel, M., Manning, J. J., Finlay, D. B., Javitch, J. A., Banister, S. D., Grimsey, N. L., & Glass, M. (2020). Signalling profiles of a structurally diverse panel of synthetic cannabinoid receptor agonists. Biochemical Pharmacology, 175, 113871. doi: 10.1016/j.bcp.2020.113871

Zhu, X., Finlay, D. B., Glass, M., & Duffull, S. B. (2020). Evaluation of the profiles of CB1 cannabinoid receptor signalling bias using joint kinetic modelling. British Journal of Pharmacology, 177, 3449-3463. doi: 10.1111/bph.15066

Finlay, D. B., Sircombe, K. J., Nimick, M., Jones, C., & Glass, M. (2020). Terpenoids from cannabis do not mediate an entourage effect by acting at cannabinoid receptors. Frontiers in Pharmacology, 11, 359. doi: 10.3389/fphar.2020.00359

Chapter in Book - Research

Hunter, M. R., Finlay, D. B., & Glass, M. (2017). Signal transduction and regulation of the cannabinoid CB1 receptor. In V. R. Preedy (Ed.), Handbook of cannabis and related pathologies: Biology, pharmacology, diagnosis, and treatment. (pp. 563-572). London, UK: Academic Press. doi: 10.1016/B978-0-12-800756-3.00069-7

Hunter, M. R., Finlay, D. B., Macdonald, C. E., Cawston, E. E., Grimsey, N. L., & Glass, M. (2017). Real-time measurement of cannabinoid receptor-mediated cAMP signaling. In P. H. Reggio (Ed.), Methods in enzymology: Cannabinoids and their receptors (Vol. 593). (pp. 43-59). Cambridge, MA: Academic Press. doi: 10.1016/bs.mie.2017.05.001

^ Top of page

Journal - Research Article

Gamage, T. F., Barrus, D. A., Kevin, R. C., Finlay, D. B., Lefever, T. W., Patel, P. R., … Glass, M., … Thomas, B. F. (2020). In vitro and in vivo pharmacological evaluation of the synthetic cannabinoid receptor agonist EG-018. Pharmacology Biochemistry & Behavior, 193, 172918. doi: 10.1016/j.pbb.2020.172918

Finlay, D. B., Sircombe, K. J., Nimick, M., Jones, C., & Glass, M. (2020). Terpenoids from cannabis do not mediate an entourage effect by acting at cannabinoid receptors. Frontiers in Pharmacology, 11, 359. doi: 10.3389/fphar.2020.00359

Zhu, X., Finlay, D. B., Glass, M., & Duffull, S. B. (2020). Evaluation of the profiles of CB1 cannabinoid receptor signalling bias using joint kinetic modelling. British Journal of Pharmacology, 177, 3449-3463. doi: 10.1111/bph.15066

Patel, M., Manning, J. J., Finlay, D. B., Javitch, J. A., Banister, S. D., Grimsey, N. L., & Glass, M. (2020). Signalling profiles of a structurally diverse panel of synthetic cannabinoid receptor agonists. Biochemical Pharmacology, 175, 113871. doi: 10.1016/j.bcp.2020.113871

Mielnik, C. A., Sugamori, K. S., Finlay, D. B., Thorpe, H. H. A., Schapira, M., Sivananthan, N., … Glass, M., … Ross, R. A. (2020). A novel allosteric modulator of the cannabinoid CB1 receptor ameliorates hyperdopaminergia endophenotypes in rodent models. Neuropsychopharmacology. Advance online publication. doi: 10.1038/s41386-020-00876-5

Zhu, X., Finlay, D. B., Glass, M., & Duffull, S. B. (2019). An intact model for quantifying functional selectivity. Scientific Reports, 9, 2557. doi: 10.1038/s41598-019-39000-z

Zhu, X., Finlay, D. B., Glass, M., & Duffull, S. B. (2019). Model-free and kinetic modelling approaches for characterising non-equilibrium pharmacological pathway activity: Internalisation of cannabinoid CB1 receptors. British Journal of Pharmacology, 176, 2593-2607. doi: 10.1111/bph.14684

Ibsen, M. S., Finlay, D. B., Patel, M., Javtich, J. A., Glass, M., & Grimsey, N. L. (2019). Cannabinoid CB1 and CB2 receptor-mediated arrestin translocation: Species, subtype, and agonist-dependence. Frontiers in Pharmacology, 10, 350. doi: 10.3389/fphar.2019.00350

Finlay, D. B., Manning, J. J., Ibsen, M. S., Macdonald, C. E., Patel, M., Javitch, J. A., … Glass, M. (2019). Do toxic synthetic cannabinoid receptor agonists have signature in vitro activity profiles? A case study of AMB-FUBINACA. ACS Chemical Neuroscience, 10, 4350-4360. doi: 10.1021/acschemneuro.9b00429

Zhu, X., Finlay, D. B., Glass, M., & Duffull, S. B. (2018). An evaluation of the operational model when applied to quantify functional selectivity. British Journal of Pharmacology, 175, 1654-1668. doi: 10.1111/bph.14171

Finlay, D. B., Cawston, E. E., Grimsey, N. L., Hunter, M. R., Korde, A., Vemuri, V. K., … Glass, M. (2017). Gαs signalling of the CB1 receptor and the influence of receptor number. British Journal of Pharmacology, 174(15), 2545-2562. doi: 10.1111/bph.13866

Soethoudt, M., Grether, U., Fingerle, J., Grim, T. W., Fezza, F., de Petrocellis, L., … Finlay, D., … Glass, M., & van der Stelt, M. (2017). Cannabinoid CB2 receptor ligand profiling reveals biased signalling and off-target activity. Nature Communications, 8, 13958. doi: 10.1038/ncomms13958

Finlay, D. B., Joseph, W. R., Grimsey, N. L., & Glass, M. (2016). GPR18 undergoes a high degree of constitutive trafficking but is unresponsive to N-arachidonoyl glycine. PeerJ, 2016(4), e1835. doi: 10.7717/peerj.1835

MacDonald, C., Finlay, D. B., Jabed, A., Glass, M., & Graham, E. S. (2014). Development of positive control tissue for in situ hybridisation using Alvetex scaffolds. Journal of Neuroscience Methods, 238, 70-77. doi: 10.1016/j.jneumeth.2014.09.006

^ Top of page

Journal - Research Other

Finlay, D. B., Duffull, S. B., & Glass, M. (2020). 100 years of modelling ligand-receptor binding and response: A focus on GPCRs. British Journal of Pharmacology, 177, 1472-1484. doi: 10.1111/bph.14988

More publications...